NCT03528408 2023-04-11Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaHoosier Cancer Research NetworkPhase 2 Unknown52 enrolled
NCT02913417 2021-04-19Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesCalifornia Pacific Medical Center Research InstitutePhase 1/2 Unknown26 enrolled